Key facts
- This page summarizes Arjun Goyal's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 04 Jun 2021, 17:00.
Arjun Goyal - 02 Jun 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Director
- Issuer ticker
- CNTA
- Reported as of
- 02 Jun 2021
- Net transaction value
- +$49,999,998
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2021, 17:00:38 UTC
- Prior SEC filing
- 27 May 2021
- Next SEC filing
- 06 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marella Thorell, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Arjun Goyal filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 04 Jun 2021.
Change
- Previous filing in this sequence was filed on 27 May 2021.
- Current net transaction value: +$49,999,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Conversion of derivative security
- Transaction value
- Shares
- +3,095,909
- Change %
- Price
- Shares after
- 3,095,909
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
CNTA
transaction
Ordinary Shares
Conversion of derivative security
- Transaction value
- Shares
- +85,909
- Change %
- Price
- Shares after
- 85,909
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Footnotes
- F1, F2, F4
CNTA
transaction
Ordinary Shares
Purchase
- Transaction value
- $14,595,000
- Shares
- +729,750
- Change %
- +24%
- Price
- $20.00
- Shares after
- 3,825,659
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Footnotes
- F1, F3
CNTA
transaction
Ordinary Shares
Purchase
- Transaction value
- $405,000
- Shares
- +20,250
- Change %
- +24%
- Price
- $20.00
- Shares after
- 106,159
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTA
transaction
Derivative
Series A Preferred Shares
Award
- Transaction value
- $34,054,999
- Shares
- +3,095,909
- Change %
- Price
- $11.00
- Shares after
- 3,095,909
- Date
- 29 Jan 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,095,909
- Exercise price
- Footnotes
- F1, F2, F3, F5, F6
CNTA
transaction
Derivative
Series A Preferred Shares
Award
- Transaction value
- $944,999
- Shares
- +85,909
- Change %
- Price
- $11.00
- Shares after
- 85,909
- Date
- 29 Jan 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 85,909
- Exercise price
- Footnotes
- F1, F2, F4, F5, F6
CNTA
transaction
Derivative
Series A Preferred Shares
Conversion of derivative security
- Transaction value
- $0
- Shares
- -3,095,909
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,095,909
- Exercise price
- Footnotes
- F1, F2, F3
CNTA
transaction
Derivative
Series A Preferred Shares
Conversion of derivative security
- Transaction value
- $0
- Shares
- -85,909
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Jun 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 85,909
- Exercise price
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.
Footnote F3
Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F4
Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F5
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
Footnote F6
On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.